Management of Takayasu Arteritis with Multi-Organ Critical Illness

Immediate Life-Threatening Priorities

Check creatine kinase (CK) levels immediately—values >5,000 U/L confirm rhabdomyolysis, and aggressive IV fluid resuscitation with normal saline at 200-300 mL/hour should be initiated to maintain urine output >200-300 mL/hour and prevent myoglobin-induced acute tubular necrosis, as recommended by the American College of Rheumatology 1
Acute Kidney Injury (AKI) in this context has multiple etiologies: rhabdomyolysis, renal artery stenosis from Takayasu arteritis, and possible cardiorenal syndrome from myocardial injury, and avoiding nephrotoxic agents and renally dosing all medications is crucial, according to the National Kidney Foundation 1
CT angiography of coronary arteries and thoracic aorta should be performed to identify stenosis, occlusion, or aneurysm, as suggested by the American Heart Association 1

CRP of 291 mg/L indicates highly active inflammatory disease, and performing four-extremity blood pressure measurements to detect >10 mmHg discrepancy between arms is essential, as recommended by the American College of Rheumatology 1
Auscultate for vascular bruits over subclavian arteries, carotids, and abdominal aorta, and assess all peripheral pulses for diminished or absent pulses, according to the American College of Cardiology 1
Obtain CT angiography or MR angiography of entire aorta and major branches to document extent of stenosis, occlusion, or aneurysm formation, as suggested by the American College of Radiology 2

Immediately initiate high-dose oral prednisone 1 mg/kg/day (40-60 mg daily) combined with methotrexate 20-25 mg weekly, as recommended by the American College of Rheumatology 2
Do NOT use glucocorticoid monotherapy—combination therapy reduces long-term glucocorticoid toxicity and improves outcomes, according to the European League Against Rheumatism 1
Given life-threatening organ involvement, consider IV methylprednisolone 500-1,000 mg/day for 3-5 days before transitioning to oral prednisone, as suggested by the American College of Rheumatology 1

Initial approach is medical management with antihypertensive drugs plus immunosuppressive therapy rather than immediate surgical or catheter-based intervention, as recommended by the American College of Cardiology 2
Control vascular inflammation first to improve renal blood flow and prevent progression, according to the American Heart Association 2
Consider renal artery revascularization (angioplasty/stenting or surgical bypass) only if hypertension remains refractory despite optimized medical management AND optimized immunosuppressive therapy, as suggested by the American College of Cardiology 2

Obtain carotid and vertebral artery imaging (CT/MR angiography or ultrasound) to identify stenosis or occlusion, as recommended by the American Stroke Association 1
For asymptomatic cranial/cervical vessel stenosis, medical management is preferred over surgical intervention, according to the American Heart Association 2
Continue antiplatelet therapy (aspirin) indefinitely given history of CVA and active large vessel vasculitis, as suggested by the American College of Cardiology 1

CRP and ESR are normal in 50% of patients with active Takayasu arteritis, and disease activity assessment requires clinical symptoms, vascular examination findings, and imaging evidence of new or progressive vascular lesions, as recommended by the American College of Rheumatology 1
Observational studies show significantly worse outcomes when vascular surgery is performed during active disease, according to the American College of Surgeons 2
Current CRP of 291 mg/L indicates highly active disease—any elective revascularization must wait until CRP normalizes and imaging shows quiescent disease, as suggested by the American College of Cardiology 2

After achieving remission for 6-12 months, taper prednisone completely rather than maintaining low-dose therapy, as recommended by the American College of Rheumatology 1
Continue methotrexate or other steroid-sparing agent during and after glucocorticoid taper, according to the European League Against Rheumatism 1
Clinical assessment every 3-6 months during active disease, extending to every 6-12 months in established remission, with four-extremity blood pressures, vascular examination, and inflammatory markers at each visit, as suggested by the American College of Rheumatology 1